FDA Panel Endorses Replimune Skin Cancer Therapy Ahead of Final Decision

Woburn, Friday, 31 July 2026.
An FDA advisory panel voted 10–3 supporting Replimune’s skin cancer drug RP1, overcoming previous rejections and agency skepticism ahead of the August 2 final approval decision.